Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Umbilical cord mesenchymal stem cells (UC-MSCs) are multipotent stromal cells derived from the Wharton's jelly of the human umbilical cord. This specific cell therapy candidate, developed by the Japanese biotechnology company CTEX (Cell Therapy EXpress), is currently in preclinical development. UC-MSCs are characterized by their high proliferative capacity, low immunogenicity, and potent immunomodulatory properties. They function primarily through paracrine signaling, secreting a wide array of anti-inflammatory cytokines, chemokines, and growth factors that suppress the activation of T cells, B cells, and natural killer cells while promoting the induction of regulatory T cells. CTEX focuses on the rapid and scalable manufacturing of these cells to address various inflammatory and autoimmune conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (CTEX).